SARS-CoV-2

Sorrento Announces the Publication in the Nature Journal Scientific Reports the Details of the Discovery of SARS-CoV-2 Neutralizing Antibodies from the G-MAB Library

09/21/2022

Excerpt from the Press Release: SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced publication of peer-reviewed data detailing the discovery and preclinical profiling of antibodies from the Sorrento G-MAB™ library with neutralizing activity against SARS-CoV-2 in vitro and in vivo in Scientific Reports, a Nature portfolio journal. About Sorrento…

Read More

Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19

09/16/2022

Novel Phase 3 Trial Design to Evaluate Bemnifosbuvir as Monotherapy and Combination Antiviral Therapy for COVID-19 Trial to Focus on High-Risk Patients at Greatest Risk for Disease Progression Trial Expected to Initiate in Fourth Quarter 2022 Conference Call at 8:30 a.m. ET Today Excerpt from the Press Release: BOSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) —…

Read More

Elicio Therapeutics Announces Publication of Preclinical Data on ELI-005, a Lymph Node-Targeted Amphiphile Vaccine Against SARS-CoV-2

09/12/2022

Data published in bioRxiv shows ELI-005 administration safely promotes robust cellular and humoral immunity through potent and targeted engagement of the lymph nodes in mice and non-human primates (NHPs) Prime-boost administration of ELI-005 induced potent Spike receptor binding domain (RBD)-specific effector cytokine-producing T cell responses in mouse and NHP peripheral blood showing cross-reactivity against variants…

Read More

Lucira Announces Health Canada Authorization of First and Only 99% Accurate At-Home Covid & Flu Test

08/17/2022

Excerpt from the Press Release: EMERYVILLE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) — Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today announced that Health Canada has granted Authorization under Interim Order for the emergency…

Read More

Detecting Immunity to COVID just got a Whole Lot Easier

08/12/2022

Enable Biosciences Reports Easier and Accurate SARS-CoV-2 Neutralizing Antibody Assay using Dried Blood Spot Samples Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Aug. 3, 2022 /PRNewswire/ — Scientists at Enable Biosciences report a novel method to easily, rapidly and accurately detect neutralizing antibodies against SARS-CoV-2 from dried blood spots, named “SONIA” (Split-Oligonucleotide Neighboring…

Read More

Helixmith Announces Topline Results from Double-Blind Placebo Controlled Multicenter Study for TADIOS Involving 100 Subjects Infected with COVID-19

08/11/2022

KEY POINTS TADIOS was determined to be safe and well tolerated Serum levels of IL-1RA changed significantly, a biomarker that has a correlation with severity and mortality during COVID-19 infections Improvement in fatigue observed Excerpt from the Press Release: LA JOLLA, Calif., Aug. 3, 2022  Helixmith announced topline results today from the double-blind placebo controlled…

Read More

Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19

08/04/2022

– 200mg and 400mg Once-Daily Doses Achieved Strong Exposure Multiples Over EC90 and Were Generally Safe and Well-Tolerated – Plan to Initiate Phase 2 Study in 4Q 2022 Excerpt from the Press Release: WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver…

Read More

Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19

08/02/2022

STI-1558, an oral SARS-CoV-2 main protease inhibitor which can block viral replication, is specifically designed as a standalone treatment of COVID-19. Studies to date indicate that STI-1558 does not require the co-administration of ritonavir as a booster for CYP3A4 inhibition. STI-1558 is also a Cathepsin L inhibitor, which can block effective viral entry into host…

Read More

New Collaborative Research Study Between nference and the NIH Identifies Which Mutations Enable Highly Transmissible Viruses, Like SARS-CoV-2, to Persist in Human Circulation

07/29/2022

Published in PNAS Nexus, this study has the ability to impact future research and inform more proactive and sustainable pandemic preparedness Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–nference, an AI-driven health technology company, today announced a new research partnership following the publication of a study demonstrating the value of characterizing SARS-CoV-2 viral sequences using…

Read More

CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19

07/27/2022

— If Granted by the European Commission, Veklury will Become the Only Direct-Acting Antiviral with Full Marketing Authorization in the EU — Excerpt from the Press Release: FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Commission (EC) adopted a positive…

Read More